Clinical Cancer Research Grants Advances in Breast Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Vesselle, H.
Right arrow Articles by Wood, D. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vesselle, H.
Right arrow Articles by Wood, D. E.
Clinical Cancer Research Vol. 6, 3837-3844, October 2000
© 2000 American Association for Cancer Research

Clinical Trials

Lung Cancer Proliferation Correlates with [F-18]Fluorodeoxyglucose Uptake by Positron Emission Tomography1

Hubert Vesselle2, Rodney A. Schmidt, Jeffrey M. Pugsley, Melissa Li, Steve G. Kohlmyer, Eric Vallières and Douglas E. Wood

Department of Radiology, Division of Nuclear Medicine [H. V., J. M. P., S. G. K.], Department of Pathology [R. A. S., M. L.], and Division of Thoracic Surgery [E. V., D. E. W.], University of Washington, Seattle, Washington 98195

Tumor proliferation has prognostic value in resected early-stage non-small cell lung cancer (NSCLC). We evaluated whether [F-18]fluorodeoxyglucose (FDG) uptake of NSCLC correlates with tumor proliferation and, thus, could noninvasively grade NSCLCs (refining patient prognosis and therapy). Thirty-nine patients with potentially resectable NSCLC underwent whole-body FDG positron emission tomography (PET) 45 min after i.v. injection of 10 mCi of FDG. Tumor FDG uptake was quantitated with the maximum pixel standardized uptake value (maxSUV). The lesion diameter from computed tomography was used to correct the maxSUV for partial volume effects using recovery coefficients determined for the General Electric Advance PET scanner. Thirty-eight patients underwent complete surgical staging (bronchoscopy and mediastinoscopy, with or without thoracotomy). One stage IV patient by PET underwent bronchoscopic biopsy only. Immunohistochemistry for Ki-67 (proliferation index marker) was performed on all of the 39 NSCLC specimens (35 resections, 1 percutaneous, and 3 surgical biopsies). The specimens were reviewed for cellular differentiation (poor, moderate, well) and tumor type. Lesions ranged from 0.7 to 6.1 cm. The correlation found between uncorrected maxSUV and lesion size (Rho, 0.56; P = 0.0006) disappeared when applying the recovery coefficients (Rho, -0.035; P = 0.83). Ki-67 expression (percentage of positive cells) correlated strongly with FDG uptake (corrected maxSUV: Rho, 0.73; P < 0.0001). The correlation was stronger for stage I lesions (11 stage IA, 15 stage IB): Rho, 0.79; P < 0.0001) and strongest in stage IB (Rho, 0.83; P = 0.0019). A significant association (P < 0.0001) between tumor differentiation and corrected SUV was noted. FDG PET may be used to noninvasively assess NSCLC proliferation in vivo, identifying rapidly growing NSCLCs with poor prognosis that could benefit from preoperative chemotherapy.




This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
Y. J. Lee, A. Cho, B. C. Cho, M. Yun, S. K. Kim, J. Chang, J. W. Moon, I. K. Park, H. J. Choi, and J.-H. Kim
High Tumor Metabolic Activity as Measured by Fluorodeoxyglucose Positron Emission Tomography Is Associated with Poor Prognosis in Limited and Extensive Stage Small-Cell Lung Cancer
Clin. Cancer Res., April 1, 2009; 15(7): 2426 - 2432.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
C. Juhasz, O. Muzik, X. Lu, M. S. Jahania, A. O. Soubani, M. Khalaf, F. Peng, T. J. Mangner, P. K. Chakraborty, and D. C. Chugani
Quantification of Tryptophan Transport and Metabolism in Lung Tumors Using PET
J. Nucl. Med., March 1, 2009; 50(3): 356 - 363.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Neuroradiol.Home page
S. Bisdas, K. Spicer, and Z. Rumboldt
Whole-Tumor Perfusion CT Parameters and Glucose Metabolism Measurements in Head and Neck Squamous Cell Carcinomas: A Pilot Study Using Combined Positron-Emission Tomography/CT Imaging
AJNR Am. J. Neuroradiol., August 1, 2008; 29(7): 1376 - 1381.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Neuroradiol.Home page
T. Kato, J. Shinoda, N. Nakayama, K. Miwa, A. Okumura, H. Yano, S. Yoshimura, T. Maruyama, Y. Muragaki, and T. Iwama
Metabolic Assessment of Gliomas Using 11C-Methionine, [18F] Fluorodeoxyglucose, and 11C-Choline Positron-Emission Tomography
AJNR Am. J. Neuroradiol., June 1, 2008; 29(6): 1176 - 1182.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
I. I. Na, B. H. Byun, H. J. Kang, G. J. Cheon, J. S. Koh, C. H. Kim, D. H. Choe, B.-Y. Ryoo, J. C. Lee, S. M. Lim, et al.
18F-Fluoro-2-Deoxy-Glucose Uptake Predicts Clinical Outcome in Patients with Gefitinib-Treated Non-Small Cell Lung Cancer
Clin. Cancer Res., April 1, 2008; 14(7): 2036 - 2041.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
K. Kaira, N. Oriuchi, Y. Otani, K. Shimizu, S. Tanaka, H. Imai, N. Yanagitani, N. Sunaga, T. Hisada, T. Ishizuka, et al.
Fluorine-18-{alpha}-Methyltyrosine Positron Emission Tomography for Diagnosis and Staging of Lung Cancer: A Clinicopathologic Study
Clin. Cancer Res., November 1, 2007; 13(21): 6369 - 6378.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
P. C. Lee, J. L. Port, R. J. Korst, Y. Liss, D. N. Meherally, and N. K. Altorki
Risk Factors for Occult Mediastinal Metastases in Clinical Stage I Non-Small Cell Lung Cancer
Ann. Thorac. Surg., July 1, 2007; 84(1): 177 - 181.
[Abstract] [Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
R. J. Downey, T. Akhurst, M. Gonen, B. Park, and V. Rusch
Fluorine-18 fluorodeoxyglucose positron emission tomographic maximal standardized uptake value predicts survival independent of clinical but not pathologic TNM staging of resected non-small cell lung cancer
J. Thorac. Cardiovasc. Surg., June 1, 2007; 133(6): 1419 - 1427.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
M. Soret, S. L. Bacharach, and I. Buvat
Partial-Volume Effect in PET Tumor Imaging
J. Nucl. Med., June 1, 2007; 48(6): 932 - 945.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
W. A. Weber, J. Czernin, and M. E. Phelps
Prognostic Significance of Fluorodeoxyglucose Uptake in Non-Small Cell Lung Cancer. A Blurry Picture?
Clin. Cancer Res., June 1, 2007; 13(11): 3105 - 3106.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
H. Vesselle, J. D. Freeman, L. Wiens, J. Stern, H. Q. Nguyen, S. E. Hawes, P. Bastian, A. Salskov, E. Vallieres, and D. E. Wood
Fluorodeoxyglucose Uptake of Primary Non-Small Cell Lung Cancer at Positron Emission Tomography: New Contrary Data on Prognostic Role
Clin. Cancer Res., June 1, 2007; 13(11): 3255 - 3263.
[Abstract] [Full Text] [PDF]

Home page
 RadiologyHome page
H. Hricak, P. L. Choyke, S. C. Eberhardt, S. A. Leibel, and P. T. Scardino
Imaging Prostate Cancer: A Multidisciplinary Perspective
Radiology, April 1, 2007; 243(1): 28 - 53.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
H. Schoder and M. Gonen
Screening for Cancer with PET and PET/CT: Potential and Limitations
J. Nucl. Med., January 1, 2007; 48(1_suppl): 4S - 18S.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
K.-H. Lee, S.-H. Lee, D.-W. Kim, W. J. Kang, J.-K. Chung, S.-A. Im, T.-Y. Kim, Y. W. Kim, Y.-J. Bang, and D. S. Heo
High fluorodeoxyglucose uptake on positron emission tomography in patients with advanced non-small cell lung cancer on platinum-based combination chemotherapy.
Clin. Cancer Res., July 15, 2006; 12(14): 4232 - 4236.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
K.-i. Watanabe, H. Nomori, T. Ohtsuka, T. Naruke, A. Ebihara, H. Orikasa, K. Yamazaki, K. Uno, T. Kobayashi, and T. Goya
[F-18]Fluorodeoxyglucose Positron Emission Tomography Can Predict Pathological Tumor Stage and Proliferative Activity Determined by Ki-67 in Clinical Stage IA Lung Adenocarcinomas
Jpn. J. Clin. Oncol., July 1, 2006; 36(7): 403 - 409.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
L. K. Shankar, J. M. Hoffman, S. Bacharach, M. M. Graham, J. Karp, A. A. Lammertsma, S. Larson, D. A. Mankoff, B. A. Siegel, A. Van den Abbeele, et al.
Consensus Recommendations for the Use of 18F-FDG PET as an Indicator of Therapeutic Response in Patients in National Cancer Institute Trials
J. Nucl. Med., June 1, 2006; 47(6): 1059 - 1066.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. Pottgen, S. Levegrun, D. Theegarten, S. Marnitz, S. Grehl, R. Pink, W. Eberhardt, G. Stamatis, T. Gauler, G. Antoch, et al.
Value of 18F-Fluoro-2-Deoxy-D-Glucose-Positron Emission Tomography/Computed Tomography in Non-Small-Cell Lung Cancer for Prediction of Pathologic Response and Times to Relapse after Neoadjuvant Chemoradiotherapy
Clin. Cancer Res., January 1, 2006; 12(1): 97 - 106.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
H. Nomori, N. Kosaka, K. Watanabe, T. Ohtsuka, T. Naruke, T. Kobayashi, and K. Uno
11C-Acetate Positron Emission Tomography Imaging for Lung Adenocarcinoma 1 to 3 cm in Size With Ground-Glass Opacity Images on Computed Tomography
Ann. Thorac. Surg., December 1, 2005; 80(6): 2020 - 2025.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
B. Scher, M. Seitz, M. Reiser, E. Hungerhuber, K. Hahn, R. Tiling, P. Herzog, M. Reiser, P. Schneede, and S. Dresel
18F-FDG PET/CT for Staging of Penile Cancer
J. Nucl. Med., September 1, 2005; 46(9): 1460 - 1465.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
W. Chen, T. Cloughesy, N. Kamdar, N. Satyamurthy, M. Bergsneider, L. Liau, P. Mischel, J. Czernin, M. E. Phelps, and D. H.S. Silverman
Imaging Proliferation in Brain Tumors with 18F-FLT PET: Comparison with 18F-FDG
J. Nucl. Med., June 1, 2005; 46(6): 945 - 952.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. Leyton, J. R. Latigo, M. Perumal, H. Dhaliwal, Q. He, and E. O. Aboagye
Early Detection of Tumor Response to Chemotherapy by 3'-Deoxy-3'-[18F]Fluorothymidine Positron Emission Tomography: The Effect of Cisplatin on a Fibrosarcoma Tumor Model In vivo
Cancer Res., May 15, 2005; 65(10): 4202 - 4210.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
C. J. Jaskowiak, J. A. Bianco, S. B. Perlman, and J. P. Fine
Influence of Reconstruction Iterations on 18F-FDG PET/CT Standardized Uptake Values
J. Nucl. Med., March 1, 2005; 46(3): 424 - 428.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. Sasaki, R. Komaki, H. Macapinlac, J. Erasmus, P. Allen, K. Forster, J. B. Putnam, R. S. Herbst, C. A. Moran, D. A. Podoloff, et al.
[18F]Fluorodeoxyglucose Uptake by Positron Emission Tomography Predicts Outcome of Non-Small-Cell Lung Cancer
J. Clin. Oncol., February 20, 2005; 23(6): 1136 - 1143.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
H. Kondoh, M. E. Lleonart, J. Gil, J. Wang, P. Degan, G. Peters, D. Martinez, A. Carnero, and D. Beach
Glycolytic Enzymes Can Modulate Cellular Life Span
Cancer Res., January 1, 2005; 65(1): 177 - 185.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
F. C. Detterbeck, J. F. Vansteenkiste, D. E. Morris, C. A. Dooms, A. H. Khandani, and M. A. Socinski
Seeking a Home for a PET, Part 3: Emerging Applications of Positron Emission Tomography Imaging in the Management of Patients With Lung Cancer
Chest, November 1, 2004; 126(5): 1656 - 1666.
[Abstract] [Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
H. Nomori, K. Watanabe, T. Ohtsuka, T. Naruke, K. Suemasu, T. Kobayashi, and K. Uno
Fluorine 18-tagged fluorodeoxyglucose positron emission tomographic scanning to predict lymph node metastasis, invasiveness, or both, in clinical T1 N0 M0 lung adenocarcinoma
J. Thorac. Cardiovasc. Surg., September 1, 2004; 128(3): 396 - 401.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. J. Downey, T. Akhurst, M. Gonen, A. Vincent, M. S. Bains, S. Larson, and V. Rusch
Preoperative F-18 Fluorodeoxyglucose-Positron Emission Tomography Maximal Standardized Uptake Value Predicts Survival After Lung Cancer Resection
J. Clin. Oncol., August 15, 2004; 22(16): 3255 - 3260.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
A. K. Buck, G. Glatting, and S. N. Reske
Quantification of 18F-FDG Uptake in Non-Small Cell Lung Cancer: A Feasible Prognostic Marker?
J. Nucl. Med., August 1, 2004; 45(8): 1274 - 1276.
[Full Text] [PDF]

Home page
 JNMHome page
J. Guo, K. Higashi, H. Yokota, Y. Nagao, Y. Ueda, Y. Kodama, M. Oguchi, S. Taki, H. Tonami, and I. Yamamoto
In Vitro Proton Magnetic Resonance Spectroscopic Lactate and Choline Measurements, 18F-FDG Uptake, and Prognosis in Patients with Lung Adenocarcinoma
J. Nucl. Med., August 1, 2004; 45(8): 1334 - 1339.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
H. Vesselle, E. Turcotte, L. Wiens, R. Schmidt, J. E. Takasugi, T. Lalani, E. Vallieres, and D. E. Wood
Relationship between Non-Small Cell Lung Cancer Fluorodeoxyglucose Uptake at Positron Emission Tomography and Surgical Stage with Relevance to Patient Prognosis
Clin. Cancer Res., July 15, 2004; 10(14): 4709 - 4716.
[Abstract] [Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
G. Halter, A. K. Buck, H. Schirrmeister, I. Wurziger, F. Liewald, G. Glatting, B. Neumaier, L. Sunder-Plassmann, S. N. Reske, and M. Hetzel
[18F] 3-deoxy-3'-fluorothymidine positron emission tomography: Alternative or diagnostic adjunct to 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography in the workup of suspicious central focal lesions?
J. Thorac. Cardiovasc. Surg., April 1, 2004; 127(4): 1093 - 1099.
[Abstract] [Full Text] [PDF]

Home page
 RadioGraphicsHome page
V. Kapoor, B. M. McCook, and F. S. Torok
An Introduction to PET-CT Imaging
RadioGraphics, March 1, 2004; 24(2): 523 - 543.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
H. Vesselle, E. Turcotte, L. Wiens, and D. Haynor
Application of a Neural Network to Improve Nodal Staging Accuracy with 18F-FDG PET in Non-Small Cell Lung Cancer
J. Nucl. Med., December 1, 2003; 44(12): 1918 - 1926.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
A. K. Buck, G. Halter, H. Schirrmeister, J. Kotzerke, I. Wurziger, G. Glatting, T. Mattfeldt, B. Neumaier, S. N. Reske, and M. Hetzel
Imaging Proliferation in Lung Tumors with PET: 18F-FLT Versus 18F-FDG
J. Nucl. Med., September 1, 2003; 44(9): 1426 - 1431.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
H. Vesselle, J. Grierson, M. Muzi, J. M. Pugsley, R. A. Schmidt, P. Rabinowitz, L. M. Peterson, E. Vallieres, and D. E. Wood
In Vivo Validation of 3'deoxy-3'-[18F]fluorothymidine ([18F]FLT) as a Proliferation Imaging Tracer in Humans: Correlation of [18F]FLT Uptake by Positron Emission Tomography with Ki-67 Immunohistochemistry and Flow Cytometry in Human Lung Tumors
Clin. Cancer Res., November 1, 2002; 8(11): 3315 - 3323.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. K. Buck, H. Schirrmeister, M. Hetzel, M. von der Heide, G. Halter, G. Glatting, T. Mattfeldt, F. Liewald, S. N. Reske, and B. Neumaier
3-Deoxy-3-[18F]Fluorothymidine-Positron Emission Tomography for Noninvasive Assessment of Proliferation in Pulmonary Nodules
Cancer Res., June 1, 2002; 62(12): 3331 - 3334.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
D. A. Mankoff, L. K. Dunnwald, J. R. Gralow, G. K. Ellis, A. Charlop, T. J. Lawton, E. K. Schubert, J. Tseng, and R. B. Livingston
Blood Flow and Metabolism in Locally Advanced Breast Cancer: Relationship to Response to Therapy
J. Nucl. Med., April 1, 2002; 43(4): 500 - 509.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
E. Salminen and M. Mac Manus
FDG-PET imaging in the management of non-small-cell lung cancer
Ann. Onc., March 1, 2002; 13(3): 357 - 360.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
K. Higashi, Y. Ueda, Y. Arisaka, T. Sakuma, Y. Nambu, M. Oguchi, H. Seki, S. Taki, H. Tonami, and I. Yamamoto
18F-FDG Uptake as a Biologic Prognostic Factor for Recurrence in Patients with Surgically Resected Non-Small Cell Lung Cancer
J. Nucl. Med., January 1, 2002; 43(1): 39 - 45.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2000 by the American Association for Cancer Research.